Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE)

Launched by IMPERIAL COLLEGE LONDON · Sep 19, 2014

Keywords

ClinConnect Summary

The SERENADE trial is studying how to better detect liver metastases (cancer that has spread to the liver) in patients with high-risk colorectal cancer. After surgery, eligible participants will undergo special MRI scans every six months for three years to monitor for any signs of cancer spreading to the liver. This trial is important because it aims to improve the way doctors can find and manage liver metastases early, which can help in making treatment decisions.

To be eligible for this trial, participants need to have a high-risk colorectal cancer that has not yet spread to the liver, as confirmed by previous tests. They must also be at least 16 years old and able to undergo treatment if liver metastases are found. Throughout the trial, patients can expect to receive regular MRI scans, with the results shared with their healthcare team to ensure appropriate management. It's important to note that this trial is currently recruiting participants and is open to individuals of all genders.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Have a high risk primary colorectal malignancy
• • 2. Have a negative CT or includes no confirmatory evidence of liver metastases
• • 3. Is able to undergo treatment if liver metastasis is found
• • 4. Have provided written informed consent to participate in the study
• • 5. Be aged 16 years or over
• Exclusion Criteria:
• • 1. Have had a previous colorectal malignancy
• • 2. Have metastatic disease
• • 3. Have a synchronous second malignancy
• • 4. Are contraindicated for MRI
• • 5. Has a T3b or below low rectal tumour without EMVI or N1c